Back to CSTLView full pipeline
Phase 3
Development Phase
0
Upcoming Catalysts
0
Historical Events
0
Regulatory Approvals
No Catalysts Found
No catalyst events have been recorded for this drug yet.
Competitive Landscape
0 competitors in Recessive Dystrophic Epidermolysis Bullosa
View Full LandscapeDrug Information
Target Indication
Recessive Dystrophic Epidermolysis Bullosa
Clinical Trial
NCT04213261Last updated: 1/17/2026
Patent & Exclusivity
No patent data available. Pre-approval drugs may not have Orange Book listings.
Drug Science
Mechanism of action & safety profile
Related Pipeline
D-FiPhase 3
Dystrophic Epidermolysis Bullosa
Autologous Human Fibroblast (azficel-T)Phase 3
Bilateral Nasolabial Fold Wrinkles
Autologous Human Fibroblasts (azficel-T)Phase 3
Acne Scarring of the Face
Azficel-T (autologous fibroblasts)Phase 2
Dysphonia Resulting From Vocal Fold Scarring
diacerein 1% ointmentPhase 2
Epidermolysis Bullosa
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts